Browsing: cost-effectiveness
Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September.…
Amid increased concern about the costs of using glucagon-like peptide 1 agonists to treat obesity, some insurers are imposing further…
The Food and Drug Administration approved Winrevair last week. The drug is indicated for a rare and deadly cardiovascular disorder…
The U.S. House of Representatives passed H.R. 485, the Protecting Health Care for All Patients Act, this week. The bill…
A push to lift Medicare’s prohibition on coverage of weight loss drugs is picking up steam in Congress. The history…